[1] RANE CK,MINDEN A.p21 activated kinase signaling in cancer [J].Semin Cancer Biol,2019,54(1):40-49.
[2] WANG Y,GUO FH.Group I PAKs in myelin formation and repair of the central nervous system:what,when,and how [J].Biological Reviews of the Cambridge Philosophical Society,2022,97(2):615-639.
[3] LIU H,LIU KD,DONG ZG.The role of p21-activated kinases in cancer and beyond:Where are we heading [J].Frontiers in Cell and Developmental Biology,2021,9(1):641381-641382.
[4] MONTALTO FI,DE AMICIS F.Cyclin D1 in cancer:A molecular connection for cell cycle control,adhesion and invasion in tumor and stroma [J].Cells,2020,9(12):2648-2649.
[5] RAMOS-GARCIA P,GIL-MONTOYA JA,SCULLY C,et al.An update on the implications of cyclin D1 in oral carcinogenesis [J].Oral Dis,2017,23(7):897-912.
[6] RADENKOVIC S,KONJEVIC G,NIKITOVIC M,et al.Evaluation of Cyclin D1 expression by western blotting methods and immunohistochemistry in breast cancer patients [J].Journal of Buon,2021,26(2):475-482.
[7] CHU C,GENG Y,ZHOU Y,et al.Cyclin E in normal physiology and disease states [J].Trends Cell Biol,2021,31(9):732-746.
[8] PANG W,LI Y,GUO W,et al.Cyclin E:a potential treatment target to reverse cancer chemoresistance by regulating the cell cycle [J].Am J Transl Res,2020,2(9):5170-5187.
[9] CARUSO JA,DUONG MT,CAREY JPW,et al.Low-molecular-weight cyclin E in human cancer:Cellular consequences and opportunities for targeted therapies [J].Cancer Res,2018,78(19):5481-5491.
[10] LIU DG,KANG HX,GAO MT,et al.Exosome-transmitted circ_MMP2 promotes hepatocellular carcinoma metastasis by upregulating MMP2 [J].Mol Oncol,2020,14(6):1365-1380.
[11] YAN Y,FANG LI,LI YX,et al.Association of MMP2 and MMP9 gene polymorphisms with the recurrent spontaneous abortion:A meta-analysis [J].Gene,2021,767(1):145173-145174.
[12] JIANG H,LI H.Prognostic values of tumoral MMP2 and MMP9 overexpression in breast cancer:a systematic review and meta-analysis [J].BMC Cancer,2021,21(1):149-150.
[13] SANYAL S,AMIN SA,ADHIKARI N,et al.Ligand-based design of anticancer MMP2 inhibitors:a review [J].Future Med Chem,2021,13(22):1987-2013.
[14] WANG X,YANG B,SHE Y,et al.The lncRNA TP73-AS1 promotes ovarian cancer cell proliferation and metastasis via modulation of MMP2 and MMP9 [J].J Cell Biochem,2018,119(9):7790-7799.
[15] JOSEPH C,ALSALEEM M,ORAH N,et al.Elevated MMP9 expression in breast cancer is a predictor of shorter patient survival [J].Breast Cancer Res Treat,2020,182(2):267-282.
[16] MONDAL S,ADHIKARI N,BANERJEE S,et al.Matrix metalloproteinase-9(MMP-9) and its inhibitors in cancer:A minireview [J].Eur J Med Chem,2020,194(1):112260-112261.
[17] AKULA SM,ABRAMS SL,STEELMAN LS,et al.RAS/RAF/MEK/ERK,PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma [J].Expert Opin Ther Targets,2019,23(11):915-929.
[18] MAZEIN A,ROUGNY A,KARR JR,et al.Reusability and composability in process description maps:RAS-RAF-MEK-ERK signaling [J].Brief Bioinform,2021,22(5):103-104.
[19] HAN J,LIU Y,YANG S,et al.MEK inhibitors for the treatment of non-small cell lung cancer [J].J Hematol Oncol,2021,14(1):1-2.
[20] WEN Z,JIANG R,HUANG Y,et al.Inhibition of lung cancer cells and Ras/Raf/MEK/ERK signal transduction by ectonucleoside triphosphate phosphohydrolase-7(ENTPD7) [J].Respir Res,2019,20(1):194-195.
[21] ROSKOSKI R JR.Targeting oncogenic Raf protein-serine/threonine kinases in human cancers [J].Pharmacol Res,2018,135(1):239-258.